Transcript Pharmaceuticals and medicine

THE BIOTECH INDUSTRY:
Firms that produce, analyse, or use biological systems
on a micro-, cellular-, or molecular level or firms that develops
tools and supplies for these purposes.
Agriculture
Food
Instruments
& equipment
Pharmaceuticals
Medical Technology
Biotechnology
Forestry
Pulp & Paper
Chemistry
Environment
The Swedish biotech industry
• Agrobiotechnology - plant improvement and biological
plant protection
• Bioproduction - biomolecular or micro-organism production
• Biotech tools and supplies - services, processes,
equipment and instruments for biotechnological use
• Environmental biotechnology - soil, water, and waste
treatment
• Functional food and feed - mainly probiotics
• Pharmaceuticals and medicine - drug discovery and drug
development, diagnostics and medical technology
400
0
USA
Japan
Korea
Canada
Germany
UK
China
France
Sweden
Spain
Italy
Australia
Israel
Taiwan
Netherlands
Finland
Switzerland
Denmark
Belgium
Norway
Russia
South Africa
India
Estonia
Latvia
Lithuania
Poland
Slovakia
No. of Companies
Number of biotechnology companies
in different countries year 2000
1400
1200
1000
800
600
*
200
Country
Source: The Swedish Trade council,
”Global perspectives on bioscience 2002”
Number of companies and employees
4500
200
3975
180
160
3760
140
120
100
3233
3500
3391
3000
2677
Number of
companies
2500
2000
80
1500
60
1000
40
20
0
4000
500
0
1997
1998
1999
Year
2000
2001
Number of
employees
The regional distribution of the Swedish biotech industry 1999*
No. of employees
No. of companies
* The sizes of the circles are proportional to the number of employees/companies.
Only micro-, and small sized companies (<200 employees) are included.
The distribution is based on the seat of the county government.
Number of companies
Number of
companies
120
Agrobiotechnology
100
Bioproduction
80
Biotech tools & supplies
60
Environmental biotechnology
40
Functional food & feed
20
Pharmaceuticals & medicine
0
1997
1998
1999
Year
2000
2001
Number of employees
2500
Number of
employees
Agrobiotechnology
2000
Bioproduction
1500
Biotech tools & supplies
Environmental biotechnology
1000
Functional food & feed
500
Pharmaceuticals & medicine
0
1997
1998
1999
Year
2000
2001
Turnover
Turnover
(MSEK)
2500
Agrobiotechnology
2000
Bioproduction
1500
Biotech tools & supplies
Environmental biotechnology
1000
Functional food & feed
500
Pharmaceuticals & medicine
0
1997
1998
1999
Year
2000
Number of companies
pharmaceuticals & medicine
Number of
companies
60
50
Diagnostics
40
Drug delivery
30
Drug discovery & development
20
Medical technology
10
0
1997
1998
1999
Year
2000
2001
Number of employees in
pharmaceuticals & medicine
1200
Number of
employees 1000
Diagnostics
800
Drug delivery
600
Drug discovery & development
400
Medical technology
200
0
1997
1998
1999
Year
2000
2001
Median equity/assets ratio
80
Finacial strength,
median (%)
70
Agrobiotechnology
Bioproduction
60
Biotech tools & supplies
50
Environmental biotechnology
40
Functional food & feed
30
Pharmaceuticals & medicine
20
1997
1998
1999
Year
2000
Net profits/losses in surviving companies in
the different biotech sectors, 1998 – 2001
Agrobiotechnology
200
MSEK
0
Bioproduction
-200
Biotech tools & supplies
-400
Environmental biotechnology
-600
Functional food & feed
-800
Pharmaceuticals & medicine
-1000
Total
-1200
1998
1999
Year
2000
2001
Share of surviving companies with net profit
1998-2001 in total and in each sector
100
Per cent
Agrobiotechnology
Bioproduction
80
Biotech tools & supplies
60
Environmental biotechnology
40
Functional food & feed
20
Pharmaceuticals & medicine
Total
0
1998
1999
2000
Year
2001
Size of sector in Sweden
• PHARMACEUTICALS AND MEDICAL TECHNOLOGY
Approximately 30 000 employees and a turnover of 60 billion SEK
• BIOTECHNOLOGY
• The fourth largest biotechnology industry in Europe after
Great Britain, Germany, and France * and the ninth in the world**
• 183 SMEs (< 500 emp. each), increase by 35% 1997-2001
• About 4000 employees, increase by 48% 1997-2001
• Turnover 4.4 billion SEK (2000), increase by 30 % 1997-2000***
• Increased financial strength and net losses 1997-2001
* European Commission; Ernst & Young
** The Swedish Trade Council
*** Fixed prices
Reasons for the development
UNTIL 1999
• The science base
• The presence of Astra and Pharmacia
• An internationally growing market
• Success stories inspires
• Changed attitudes
• Good availability of seed and venture capital
CHANGE DURING 2000-2002…2003
• Development at the stock exchange
• Cautious venture capital companies
• Lack of seed capital
The Swedish science base in international comparison
THE SWEDISH SCIENTIFIC PERFORMANCE IN GENERAL
• The trend is increased quantity but at the same time there are
signs of decreasing quality.
PERFORMANCE IN A SELECTION OF LIFE SCIENCE FIELDS
• First, second or third ranking of publication volumes in relation to
population in the selected seven subject fields.
• Five out of seven fields showed increasing shares of the world’s
total publication volume.
• Four out of seven fields showed increased citation levels but
still Swedish citation levels are loosing their top position
Swedish ranking in relation to population
1986-2001
1986- 1990- 1994- 19981989 1993 1997 2001
Total
87-01
Biochemistry & Biophysics
2
2
2
2
2
Biotechnol & Appl Microbiol
3
4
3
1
2
Cell & Developmental Biol
3
3
2
2
2
Immunology
1
2
2
2
2
Microbiology
2
2
4
3
3
Molecular Biology & Genetics
2
2
3
2
2
Neurosciences & Behavior
1
1
1
1
1
Relative citation levels in
biochemistry and biophysics
1.6
1.4
1.2
1.0
0.8
0.6
CANADA
DENMARK
EUROPEAN UNION
FINLAND
FRANCE
GERMANY
ISRAEL
NETHERLANDS
SWEDEN
SWITZERLAND
UK
USA
Relative citation levels in
neurosciences and behavior
1.4
CANADA
DENMARK
1.2
EUROPEAN UNION
FINLAND
1.0
FRANCE
GERMANY
0.8
ISRAEL
NETHERLANDS
0.6
SWEDEN
SWITZERLAND
0.4
UK
USA
Volume shares for the nine most productive Swedish public
research organisations of the total Swedish publication volume
in biotechnology-related science, 1987-2001
Per cent
40
35
KAROLINSKA
INST
LUND UNIV
30
UPPSALA UNIV
25
GOTHENBURG
UNIV
UMEA UNIV
20
STOCKHOLM
UNIV
SLU
15
10
LINKOPING
UNIV
SMI
5
0
19871989
19901992
19931995
Year
19961998
19992001
Co-authorship pattern between organisations with the largest
publication volumes in biotechnology related science 1997-2001
The Swedish percentage of the ’world´s total
publication volume within a selection of life
science fields during five periods (1987-2001)
4
3
2
1
0
1987-1989
1990-1992
1993-1995
1996-1998
1999-2001
Relative citation levels for Swedish articles within a selection
of life science fields during 1987-1997 (Index world=1)
2
87-91
88-92
89-93
90-94
1
91-95
92-96
93-97
0
94-98
95-99
96-00
97-01
Inventor origin for biotechnology patents
in the US patent system 1987-2001*
Canada
2,6%
Other
11,0%
France
2,9%
Great Britain
3,6%
Germany
4,6%
Japan
11,4%
* Sweden < 1%
USA
63,9%
Swedish inventor shares of the world’s total patenting volume
during five periods in different areas compared to the
Swedish average share in all fields 1987-2001
3
2
1
0
1987-1989
1990-1992
1993-1995
1996-1998
1999-2001
Number of patents for Astra and Pharmacia
80
NUMBER OF PATENTS
70
60
50
AstraZeneca AB
Pharmacia Corporation
40
30
20
10
0
YEAR